Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy

Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, discusses the value of immunotherapeutic agents, including CAR-T cells and bispecific antibodies, in the treatment of patients with triple-class refractory multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.